Quanterix, which makes next-generation protein detection tests for clinical research, raised $64 million by offering 4.3 million shares at $15, within the range of $14 to $16. Quanterix plans to list on the Nasdaq under the symbol QTRX. J.P. Morgan, Leerink Partners and Cowen & Company acted as lead managers on the deal.
